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Abstract  
Previous prospective studies assessing the relationship between circulating concentrations of vitamin 
D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive 
disease. In this study, we examine the association between pre-diagnostic concentrations of 25-
hydroxyvitamin D (25(OH)D) and 1,25(OH)2D and the risk of prostate cancer overall and by tumor 
characteristics. Principal investigators of 19 prospective studies provided individual participant data 
on circulating 25(OH)D and 1,25(OH)2D for up to 13,462 men with incident prostate cancer and 
20,261 control participants. Odds ratios (OR) for prostate cancer by study-specific fifths of season-
standardized vitamin D concentration were estimated using multivariable-adjusted conditional 
logistic regression. 25(OH)D concentration was positively associated with risk for total prostate 
cancer (multivariable-adjusted OR comparing highest versus lowest study-specific fifth was 1.22, 
95% CI 1.13-1.31; P trend<0.001). However, this association varied by disease aggressiveness 
(Pheterogeneity=0.014); higher circulating 25(OH)D was associated with a higher risk of non-aggressive 
disease (OR per 80 percentile increase=1.24, 1.13-1.36) but not with aggressive disease (defined as 
stage 4, metastases, or prostate cancer death, 0.95, 0.78-1.15). 1,25(OH)2D concentration was not 
associated with risk for prostate cancer overall or by tumor characteristics. The absence of an 
association of vitamin D with aggressive disease does not support the hypothesis that vitamin D 
deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D 
concentration with a higher risk of non-aggressive prostate cancer may be influenced by detection 
bias. 
Statement of significance 
This international collaboration comprises the largest prospective study on blood vitamin D and 
prostate cancer risk and shows no association with aggressive disease but some evidence of a higher 
risk of non-aggressive disease.  
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Introduction 
It has been hypothesized that vitamin D deficiency may increase prostate cancer risk (1,2). A 
meta-analysis of 6 prospective studies published up to 2010 reported that circulating vitamin D 
concentrations were not related to prostate cancer risk (3); however, it was insufficiently powered to 
provide robust estimates of risk, especially for important disease subgroups. While the active 
hormonal form of vitamin D is 1,25-dihydroxyvitamin D (1,25(OH)2D), which is mainly formed by 
hydroxylation of 25-hydroxyvitamin D (25(OH)D) in the kidney under the control of parathyroid 
hormone, circulating 25(OH)D concentration is regarded as the most informative indicator of 
vitamin D status.  
The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative 
Group (EHNBPCCG) was established to conduct collaborative reanalyzes of individual data from 
prospective studies on the relationships of circulating hormone concentrations and nutritional 
biomarkers with prostate cancer risk (4,5). With pooled individual participant data on pre-diagnostic 
circulating 25(OH)D and 1,25(OH)2D concentrations from 19 prospective studies (with up to 13,462 
men with incident prostate cancer), this analysis aimed to provide precise estimates of the association 
of circulating vitamin D with prostate cancer risk and to investigate whether these associations 
differed by tumor characteristics or time from blood collection to diagnosis. We also examined the 
cross-sectional relationships between lifestyle factors and vitamin D concentrations.  
 
Material and methods 
Data collection 
Published and unpublished studies were eligible for the current analysis if they had data on 
pre-diagnostic circulating concentrations of 25(OH)D or 1,25(OH)2D and incident prostate cancers. 
9 
 
Studies were identified using literature search methods from computerized bibliographic systems and 
by discussion with collaborators, as described previously (4,5). Data were available for 19 
prospective studies by dataset closure in May 2018.  
Individual participant data were requested on circulating 25(OH)D and 1,25(OH)2D, date, age 
and fasting status at sample collection, marital status, ethnicity, educational attainment, family 
history of prostate cancer, height, weight, waist and hip circumference, smoking status, alcohol 
intake, and vital status. Each study also provided data on prostate cancer stage and grade and death, 
if available, and the data were harmonized in a central database. Further details on data collection 
and processing are provided in the Supplementary Methods. 
Study designs and data processing 
The characteristics of the included studies are shown in Supplementary Table 1 and details 
of the assay methods are shown in Supplementary Table 2. Most of the studies were case-control 
studies nested within prospective cohort studies. Data on the control participants from The Prostate 
Testing for Cancer and Treatment (ProtecT) trial are included in cross-sectional analyses of vitamin 
D concentrations in relation to participant characteristics, but because cases were diagnosed at the 
start of the study rather than during follow-up, these data were not included in the main risk analyses. 
Written informed consent was obtained from study participants at entry into each cohort or was 
implied by participants’ return of the enrolment questionnaire. The study protocols were approved by 
institutional review boards of each study center. 
Prostate cancer was defined as being ‘early’ stage if it was tumor-node-metastasis (TNM) 
stage T1 with no reported lymph node involvement or metastases, or stage I; ‘other localized’ stage 
if it was TNM stage T2 with no reported lymph node involvement or metastases, stage II, or the 
equivalent; ‘advanced’ stage if it was TNM stage T3 or T4 and/or N1+ and/or M1, stage III–IV, or 
the equivalent; or stage unknown. Aggressive disease was categorized as “no” for TNM stage T0, 
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T1, T2 or T3 with no reported lymph node involvement and no metastases or equivalent, “yes” for 
TNM stage T4 and/or N1+ and/or M1 and/or stage IV disease and/or death from prostate cancer, or 
“unknown”. Histological grade was defined as ‘low-intermediate’ if the Gleason sum was < 8 or 
equivalent, ‘high’ grade if the Gleason sum was ≥ 8 or equivalent, or grade “unknown”. Fatal cases 
were men who died of prostate cancer during follow-up. 
Statistical analyses 
25(OH)D and 1,25(OH)2D concentrations were log-transformed to approximate a normal 
distribution for parametric analyses. To allow for the influence of month of blood draw on 
circulating concentrations, a regression model of log-transformed vitamin D concentration by month 
of blood collection was fitted for each study. All results are presented by season-standardized 
vitamin D, unless otherwise specified.  
The main method of analysis was logistic regression conditioned on the matching variables 
within each study. Men were categorized into fifths of the distribution of 25(OH)D and 1,25(OH)2D, 
with cut-points defined by the study-specific quintiles of the distribution within control participants, 
to allow for any systematic differences between the studies in assay methods and blood sample types 
(6). Linear trends were calculated by replacing the categorical variable representing the fifths of each 
analyte with a continuous variable that was scored as 0, 0.25, 0.5, 0.75, and 1; a unit increase in this 
variable can be taken to represent an 80 percentile increase in the study-specific concentration of 
vitamin D. To examine the effects of potential confounders (other than the matching criteria, which 
were taken into account in the study design and matched analyses), conditional logistic regression 
analyses included the following covariates: age at blood collection, body mass index (BMI), height, 
marital status, educational status, and cigarette smoking, all of which were associated with prostate 
cancer risk in these analyses. 
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In a sensitivity analysis, conditional logistic regression models were also fitted using quintile 
cut-points defined by the overall distribution among the control participants in all studies combined. 
The analyses were also repeated using predefined categories for concentrations of 25(OH)D of <30, 
30-<50, 50-<75 and ≥75 nmol/L, in order to investigate risks associated with very low (deficiency), 
low (insufficiency), moderate (sufficiency) and high circulating concentrations of vitamin D based 
on the Institute of Medicine recommendations (7).  
For each analyte, heterogeneity in linear trends between studies was assessed by comparing 
the χ2 values for models with and without a (study) x (linear trend) interaction term. Tests for 
heterogeneity for the case-defined factors were obtained by fitting separate models for each subgroup 
and assuming independence of the ORs using a method analogous to a meta-analysis, in which 
controls in each matched set were assigned to the category of their matched case. Tests for 
heterogeneity for non-case defined factors were assessed with χ2 tests of interaction between 
subgroups and the binary variable.  
In order to assess potential effect modification with different biomarkers, a χ2 test of 
interaction was used to determine whether risks by study-specific thirds of 25(OH)D varied 
according to study-specific thirds of 1,25(OH)2D (and vice versa), and according to study-specific 
thirds of circulating concentrations of insulin-like growth factor-I (IGF)-I, IGF binding protein-3 
(IGFBP3), testosterone, free testosterone, sex hormone-binding globulin (SHBG) and prostate-
specific antigen (PSA), where these data were available. 
The cross-sectional associations of 25(OH)D and 1,25(OH)2D with participant characteristics 
(among controls only) were examined using analyses of variance to calculate geometric mean 
concentrations and 95% confidence intervals (CIs), adjusting for study and age at blood collection, as 
appropriate.  
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All tests of statistical significance were two-sided, and statistical significance was set at the 
5% level. All statistical tests were carried out with Stata Statistical Software, Release 14 (StataCorp, 
LP, College Station, Texas). Full details of the statistical analyses are provided in the 
Supplementary Methods. 
 
Results 
Details of the 19 participating studies are shown in Table 1. Data on 25(OH)D concentrations 
were available for 13,462 men who subsequently developed prostate cancer and 20,261 control 
participants, and for 1,25(OH)2D concentrations for 1,885 case and 2,114 control participants. Mean 
age at blood collection across the studies ranged from 46.5 (SD = 4.2) to 76.3 (3.6) years. Blood 
collection preceded prostate cancer diagnosis by an average of 8.5 years (SD = 6.0 years), although 
there was a wide variation among the studies (Table 2). On average, cases were 67.5 years old (SD = 
7.3 years) at diagnosis and most (87.1%) were diagnosed after 1994. The majority of cases with 
information on stage and grade of disease had localized (early or other localized) disease (ranging 
from 47.8% to 99.0% of case patients across studies) and low-intermediate grade tumors (ranging 
from 75.8% to 100% of case patients). Concentrations of 25(OH)D and 1,25(OH)2D varied 
significantly by month among both the cases and controls (Supplementary Figure 1). 
Associations between circulating vitamin D concentrations and prostate cancer risk 
25(OH)D concentration was linearly positively associated with risk for total prostate cancer 
(Figure 1); the multivariate-OR for prostate cancer for men in the highest compared with the lowest 
study-specific fifth was 1.22 (95% CI 1.13 to 1.31; P trend < 0.001). The association was similar 
when only the matching factors were taken into account (Supplementary Figure 2) and there was 
no evidence of heterogeneity between the contributing studies (Figure 2A). When 25(OH)D was 
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categorized into study-specific tenths, the OR for the highest versus the lowest tenth was 1.34 (1.20 
to 1.49; P trend <0.001, Supplementary Table 3). 
There was no evidence of an association between 1,25(OH)2D concentration and risk for total 
prostate cancer (see Figures 1 and 2B). The association was similar when only the matching-factors 
were taken into account (Supplementary Figure 2). 
In sensitivity analyses that used overall quintile cut-points of 25(OH)D across all studies 
combined (rather than study-specific cut-points), the ORs for total prostate cancer were materially 
unchanged (Supplementary figure 3). When the analyses were repeated using predefined cut-points 
for 25(OH)D, multivariable-adjusted ORs for total prostate cancer were 0.84 (0.76-0.93), 0.89 (0.84-
0.95) and 1.07 (1.00-1.13), respectively, for men with 25(OH)D <30 (at risk for deficiency), 30-49 
and ≥75 nmol/L compared to those with concentrations of 50-74 nmol/L (Supplementary Table 4). 
While there was no evidence of heterogeneity in the association of 25(OH)D with risk by 
stage of disease, there were differences by disease aggressiveness (P heterogeneity = 0.014): the OR 
for an 80-percentile increase in 25(OH)D was 1.24, 1.13-1.36 for non-aggressive disease (T1-
T3/N0/M0) and 0.95, 0.78-1.15 for aggressive disease (T4, N1, M1 and/or fatal prostate cancer). 
Similar differences were also seen between low-intermediate and high-grade disease, although these 
differences were not statistically significant (Figure 3). There was no association between 
circulating 25(OH)D concentrations and fatal prostate cancer (Figure 3). Supplementary Figure 4 
shows results from categorical analyses of the associations of study-specific fifths of 25(OH)D with 
risk for advanced stage, aggressive disease and high-grade prostate cancer.  
There was no evidence of heterogeneity in risk of total prostate cancer associated with 
25(OH)D according to time to diagnosis or other participant characteristics (Figure 3), including 
season of blood draw (Figure 4A) or by circulating concentrations of 1,25(OH)2D, IGF-I, IGFBP-3, 
testosterone, free testosterone, SHBG or PSA (Supplementary Table 5A to 5G).  
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For 1,25(OH)2D, there was no evidence of heterogeneity by season of blood draw (Figure 
4B), time to diagnosis or other tumor characteristics (Supplementary Figure 5). There was some 
evidence of heterogeneity by family history of prostate cancer, with a positive association for men 
with a positive family history of the disease (P heterogeneity=0.03; multivariable-adjusted OR for an 80 
percentile increase = 2.26, 95% CI 1.19-4.32, Supplementary Figure 4), although this was based on 
small numbers. There was no evidence of heterogeneity by season of blood draw (Figure 4). 
Vitamin D concentrations in relation to other participant and sample characteristics 
Concentrations of 25(OH)D and 1,25(OH)2D were significantly but not strongly correlated 
with each other (r = 0.13, p < 0.001). In the subset of control participants with data available on other 
analytes, circulating 25(OH)D concentration was weakly correlated with sex hormones and other 
analytes (Supplementary Table 6), but neither 25(OH)D nor 1,25(OH)2D concentration was 
correlated with PSA (r = 0.01 for both). After adjustment for age, 25(OH)D concentration was lower 
in men who were obese, current smokers, poorly educated, unmarried and non-drinkers (Figure 5). 
1,25(OH)2D displayed generally similar associations (Supplementary Figure 6).  
 
Discussion 
This collaborative analysis of individual participant data does not support the hypothesis that 
vitamin D deficiency and/or insufficiency increases the risk of prostate cancer. Higher 25(OH)D 
levels were associated with an increased risk of non-aggressive disease, with no association for 
aggressive disease. We also found no evidence that circulating concentration of 1,25(OH)2D was 
related to risk for prostate cancer, overall or by tumor characteristics. 
This collaborative analysis includes information from the vast majority (>90%) for 25(OH)D 
and 85% for 1,25(OH)2D of the published prospective data. Of the 24 studies with published data on 
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25(OH)D, seven did not contribute data to this collaboration, all of which had fewer than 200 
incident cases and reported inconsistent findings (8-13).  Combining the results of the current 
analyses with those of six of the seven additional studies (for whom data could be extracted to 
perform a meta-analysis), did not change the overall finding (summary relative risk of highest 
compared with the lowest fifth of 25(OH)D = 1.21, 95% CI 1.13-1.30), suggesting that inclusion of 
participant-level data from these studies would not have materially altered the results. Two studies 
with published data on 1,25(OH)2D did not contribute data, one of which reported an inverse 
association (based on 181 cases, RR not given for 1,25(OH)2D alone) (10,14) and another that found 
no association (based on 136 cases) (9). Including these two studies would not have materially 
changed our results. Thus, we believe that the findings from the current study provide a reliable 
summary of the totality of the evidence on the association between circulating vitamin D 
concentrations and prostate cancer risk.  
Our findings do not appear to support the evidence from experimental research using cell 
lines and animal models that vitamin D compounds may promote cell differentiation, inhibit prostate 
cancer cell growth and invasion, and stimulate apoptosis (15,16). While there are no published data 
from adequately powered randomized controlled trials for the effects of vitamin D supplementation 
on prostate cancer incidence, two large recent studies have exploited GWAS-identified variation in 
genes related to vitamin-D synthesis, metabolism and binding to study the possible relationship with 
prostate cancer risk. A Mendelian randomization analysis of data from up to 69,837 prostate cancer 
cases in the PRACTICAL and GAME-ON consortia found no evidence for an association with risk 
for either total (OR in PRACTICAL per genetically-determined 25 nmol/L increase in 25(OH)D 
concentration = 0.95, 95% CI 0.80-1.13; P = 0.55) or aggressive prostate cancer (OR in GAME-ON 
= 1.14, 0.85-1.54; P = 0.38) (17).  
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It is possible that our finding of a positive association between overall and non-aggressive 
prostate cancer risk and circulating 25(OH)D concentration may be explained by detection bias, in 
that health-conscious men who may be more likely to have a higher sun exposure, a higher dietary 
intake of vitamin D and/or vitamin D supplementation, are more likely to have a PSA test or to seek 
medical attention with early symptoms. The observation that vitamin D deficiency was associated 
with a reduced risk of prostate cancer and higher levels with an increased risk (particularly for non-
aggressive disease) supports this hypothesis. Nonetheless, a positive association between 25(OH)D 
and prostate cancer risk was reported in both the PLCO and PCPT studies, in which almost all men 
had either regular PSA testing (as data were provided solely from the screening arm in PLCO and 
PCPT) or had an end-of-study biopsy (PCPT), suggesting that factors other than detection bias may 
be involved.  
It is difficult to draw conclusions from the current pooled analyses of 1,25(OH)2D as only a 
small number of prospective studies have measured this analyte. While circulating 1,25(OH)2D 
concentrations are considered to be tightly regulated within a narrow range (18), we found some 
evidence of seasonal variation in 1,25(OH)2D concentrations, similar to that of 25(OH)D, and also 
differences in concentrations according to age, adiposity, cigarette smoking status and alcohol 
consumption. It is difficult to determine the extent to which these associations are due to cross-
reactivity of the 1,25(OH)2D assay with 25(OH)D (or other molecules), although the correlation 
between 25(OH)D and 1,25(OH)2D was weak (r=0.13) and there was no evidence for an association 
between 1,25(OH)2D and prostate cancer risk.  
A number of previous studies have evaluated the joint association of 25(OH)D and 
1,25(OH)2D with prostate cancer risk (9,19-21), but their sample sizes were small. We found no 
evidence that the association of prostate cancer risk with 25(OH)D is modified by circulating 
concentrations of 1,25(OH)2D, although even in this collaborative pooled dataset, there are still 
17 
 
relatively few cases (n=1,885) with data on both vitamin D analytes. It has also been hypothesized 
that vitamin D may influence tumor growth by modulating the action of growth factors, such as IGF-
I, that normally stimulate proliferation (16), for example by stimulating the release of IGFBP-3 (22). 
We observed weak correlations of circulating 25(OH)D or 1,25(OH)2D concentrations with IGF-I, 
IGFBP-1, IGFBP-2 and IGFBP-3 concentrations and with levels of other blood biomarkers (e.g. free 
testosterone or PSA), and there was no evidence of modification of the association of 25(OH)D with 
risk according to these biomarkers.  
This study has some limitations. The calculated relative risks were based on single 
measurements of vitamin D, which may not accurately reflect long-term circulating concentration. 
Several studies have found moderate correlations between two measures of 25(OH)D, even when the 
samples were not taken at the same time of the year, with correlations between 0.42 and 0.70 in 
blood taken between 3 to 14 years apart (reviewed in (23)). These findings suggest that a single 
measure of circulating 25(OH)D is an informative measure of vitamin D status, at least over the 
medium term. The published prospective data on vitamin D and risk for aggressive prostate cancer 
subtypes are still relatively limited. Thus, even in this pooled analysis, the total number of cases with 
aggressive disease and data on 25(OH)D is relatively small (n=1,446), therefore the results by tumor 
sub-type should be interpreted with some caution. Moreover, we don’t have detailed data on other 
sun exposure measures, such as solar radiation levels in each study location, which would also vary 
within each individual study depending on where each participant lives. Finally, more than 95% of 
participants included in this pooled analysis were of White ethnicity, and results may therefore not be 
generalizable to non-White populations. 
In summary, this collaborative analysis of the worldwide data on circulating vitamin D and 
prostate cancer risk suggests that a high vitamin D concentration is not associated with a lower risk 
of prostate cancer. Rather, the findings suggest that men with elevated circulating concentrations of 
18 
 
25(OH)D are more likely to be diagnosed with non-aggressive prostate cancer, though this may be 
due to detection bias. There was no evidence for an association with aggressive disease, suggesting 
that vitamin D is not casually related to the risk of prostate cancer. 
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Table 1. Participant characteristics by study and case-control statusa 
Prospective studies (First author, year) 
Case-
control 
status 
Number 
Age at 
recruitment (y) 
BMI (kg/m2) 
Married or 
cohabiting 
(%)b 
Higher 
education 
(%)b 
Current 
smoker (%)b 
Intake of 
alcohol (g/d) 
Family history 
of prostate 
cancer  (%)b 
Geometric mean 
concentration  
(95% CI) 
25(OH)Dc 
(nmol/L) 
1,25(OH)2Dc 
(pmol/L) 
ARIC (Unpublished)d Case 700 55.4 (5.7) 27.5 (4.0) 88.3 17.9 20.6 9.1 (15.9) 13.3 60.1 (58.6-61.7) - 
 Control 2752 55.2 (5.7) 27.5 (4.2) 85.8 11.6 26.9 9.9 (18.3) 6.2 59.7 (58.8-60.5) - 
ATBC (Albanes et al., 2011) Case 996 58.4 (5.2) 26.3 (3.6) 82.5 6.1 100 17.3 (23.2) 7.3 32.6 (31.4-33.8) - 
 Control 996 58.4 (5.1) 26.1 (3.7) 81.4 4.3 100 15.4 (19.5) 3.5 31.4 (30.2-32.6) - 
CLUE 1 (Braun et al., 1995) Case 61 58.3 (8.5) - 91.8 11.5 29.5 - - 82.1 (76.3-88.2) 94 (87-102) 
 Control 122 58.3 (8.5) - 86.9 9.8 25.4 - - 79.0 (74.7-83.4) 91 (85-97) 
EPIC (Travis et al., 2010) Case 652 60.4 (6.3) 26.7 (3.4) 88.8 24.9 20.3 19.1 (23.9) - 53.8 (52.3-55.3) - 
 Control 752 59.9 (6.3) 26.8 (3.5) 88.6 19.8 22.6 17.0 (19.9) - 53.2 (51.8-54.7) - 
ESTHER (Ordonez-Mena et al., 2013) Case 216 64.3 (5.1) 27.3 (3.1) 83.9 - 13.9 16.6 (19.7) 5.1 55.3 (51.7-59.1) - 
 Control 841 64.3 (5.1) 28.0 (4.2) 84.6 - 14.6 14.2 (15.3) 3.8 54.2 (52.6-55.8) - 
FMC (Unpublished)d Case 161 57.9 (10.4) 25.8 (3.1) 90.6 - 29.0 - - 51.5 (47.6-55.6) - 
 Control 286 57.2 (10.4) 26.1 (3.6) 85.0 - 34.9 - - 50.4 (47.8-53.0) - 
HIMS (Wong et al., 2014) Case 332 76.4 (3.7) 26.4 (3.5) 86.7 22.9 4.5 11.7 (15.5) - 66.8 (64.5-69.2) - 
 Control 1317 76.3 (3.6) 26.5 (3.7) 86.2 21.7 4.6 11.8 (16.1) - 64.3 (63.1-65.5) - 
HPFS (Platz et al., 2004; Mikkah et al., 
2007; Shui et al., 2012) 
Case 1326 63.8 (7.8) 26.0 (3.3) 92.7 100 4.4 11.8 (15.4) 14.4 68.1 (66.5-69.7) 83 (81-86) 
Control 1326 63.7 (7.8) 26.1 (3.5) 93.0 100 3.5 11.6 (15.8) 10.6 66.2 (64.4-68.0) 83 (81-85) 
Janus part 1 (Tuohimaa et al., 2004) Case 575 46.5 (4.3) 25.4 (3.1) - - 60.6 - - 52.1 (50.6-53.7) - 
 Control 2233 46.5 (4.2) 25.1 (3.2) - - 62.3 - - 49.7 (49.0-50.4) - 
Janus part 2 (Meyer et al., 2013) Case 2106 47.7 (9.2) 25.5 (3.0) - - 32.8 - - 60.4 (59.6-61.3) - 
 Control 2106 47.7 (9.2) 25.6 (3.0) - - 34.5 - - 58.7 (57.9-59.6) - 
JPHC (Sawada et al., 2017) Case 201 59.5 (6.4) 23.4 (2.4) 100 - 34.3 26.9 (31.7) 0.5 86.9 (82.7-91.3) - 
 Control 402 59.2 (6.6) 23.3 (2.6) 100 - 40.8 31.6 (47.6) 0.0 85.6 (82.7-88.6) - 
MCCS (Unpublished)d Case 818 58.4 (7.4) 27.1 (3.4) 82.7 30.7 8.3 17.9 (22.8) - 52.5 (51.3-53.8) - 
 Control 1151 56.4 (7.7) 26.9 (3.4) 78.2 26.9 12.9 17.8 (23.9) - 50.2 (49.1-51.2) - 
MDCS (Brandstedt et al., 2012) Case 910 61.3 (6.4) 26.3 (3.3) 77.8 14.6 22.2 14.9 (14.6) - 83.4 (81.8-85.0) - 
 Control 910 61.1 (6.4) 26.1 (3.3) 75.7 12.6 26.7 14.6 (14.2) - 82.0 (80.4-83.6) - 
MEC (Park et al., 2010) Case 329 68.9 (7.1) 26.6 (4.0) 77.1 34.0 14.1 23.3 (44.1) 13.9 77.6 (74.2-81.2) - 
 Control 656 68.7 (7.2) 26.8 (4.0) 78.6 32.9 12.6 22.5 (39.1) 8.8 75.6 (73.2-78.0) - 
 23 
PCPT (Schenk et al., 2014) Case 915 63.3 (5.5) 27.5 (4.2) 87.5 38.5 6.7 9.6 (15.8) 21.7 58.6 (57.2-60.0) - 
 Control 915 63.3 (5.5) 27.6 (4.0) 87.2 37.7 6.8 8.9 (13.7) 21.6 56.0 (54.7-57.4) - 
PHS (Gann et al., 1996; Ma et al., 1998; 
Li et al., 2007) 
Case 501 58.6 (7.6) 24.6 (2.5) - 100 7.8 7.2 (6.0) - 72.6 (70.3-75.0) 79 (77-80) 
Control 669 59.1 (7.6) 24.6 (2.5) - 100 7.0 7.1 (6.3) - 71.3 (69.3-73.3) 79 (77-80) 
PLCO (Ahn et al., 2008) Case 747 64.8 (5.0) 27.3 (3.6) 88.0 43.3 6.4 15.7 (29.5) 12.3 56.1 (54.8-57.4) - 
 Control 727 64.5 (4.9) 27.6 (3.9) 85.8 39.5 9.8 16.2 (30.1) 5.2 54.0 (52.7-55.4) - 
SELECT (Kristal et al., 2014) Case 1732 63.5 (6.1) 28.5 (4.3) 84.1 54.9 5.4 9.4 (15.7) 31.2 64.9 (63.6-66.3) - 
 Control 1732 63.6 (6.4) 28.7 (4.7) 82.6 51.0 7.1 9.2 (20.0) 15.3 63.8 (62.5-65.2) - 
SU.VI.MAX (Deschasaux et al., 2016) Case 184 54.1 (4.8) 25.5 (3.1) 93.3 30.2 11.1 25.1 (19.2) 12.7 44.1 (41.2-47.2) - 
 Control 368 53.8 (4.4) 25.7 (3.2) 89.3 26.8 12.8 25.5 (18.9) 4.4 45.9 (43.7-48.2) - 
a Values are mean (SD) unless otherwise indicated. Numbers are for men with a 25(OH)D measurement and in complete matched case-control sets. 
b Percentages exclude men with missing values. 
c 25(OH)D and 1,25(OH)D concentrations are season-standardised. 
d Unpublished vitamin D and prostate cancer data, Study references: Joshu et al., 2018 for ARIC, Knekt et al., 2008 for FMC and Milne et al., 2017 for MCCS 
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; ATBC, Alpha-Tocopherol Beta-Carotene Cancer Prevention Study; BMI, body mass index; CLUE, Campaign Against Cancer and Stroke 
(“Give Us a Clue to Cancer”) Study; EPIC, European Prospective Investigation into Cancer and Nutrition; FMC, Finnish Mobile Clinic Health Examination Survey; HIMS, Health in Men Study; HPFS, Health 
Professionals Follow-up Study; Janus part 1, Nordic Biological Specimen Biobank Working Group; Janus part 2, a second study using the Janus Serum Bank from Norway; JPHC, Japan Public Health Cohort; 
MCCS, Melbourne Collaborative Cohort Study; MDCS, Malmö Diet and Cancer Study; MEC, Multiethnic Cohort; N/A, data not available for this study; PCPT, Prostate Cancer Prevention Trial; PHS, 
Physicians Health Study; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SELECT, Selenium and Vitamin E Cancer Prevention Trial; SU.VI.MAX, Supplémentation en Vitamines et 
Minéraux Antioxydants; 25(OH)D,25-hydroxyvitamin D ; 1,25(OH)2D, 1,25-dihydroxyvitamin D. 
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Table 2. Characteristics of participants with prostate cancera 
Prospective 
studies 
Time from blood collection 
to diagnosis (%)a 
 Age at diagnosis (%)a  Year of diagnosis (%)a Disease stage, aggressiveness and grade (%) 
 <3 y 3-6 y ≥7 y  <60 y 60-69 y ≥70 y  Before 
1990 
1990-
1994 
1995-
Onward 
 Advanced 
stageb 
Unknown 
stage 
Aggressive 
diseaseb 
High 
gradeb 
Unknown 
grade 
ARIC 3.6 13.1 83.3  9.7 48.9 41.4  1.1 12.4 86.4  16.6 21.6 10.9 - 15.0 
ATBC 4.0 10.6 85.3  3.5 44.4 52.1  5.3 15.2 79.5  52.2 19.3 39.1 11.8 21.5 
CLUE I 0.0 1.6 98.4  8.2 23.0 68.9  59.0 41.0 0.0  23.5 16.4 37.7 5.1 3.3 
EPIC 33.1 50.9 16.0  17.2 62.6 20.3  0.0 0.8 99.2  26.2 28.7 21.3 10.4 16.1 
ESTHER 24.1 38.4 37.5  2.3 44.0 53.7  0.0 0.0 100  - 100 11.6 - 100 
FMC 6.2 16.8 77.0  10.6 34.2 55.3  87.0 13.0 0.0  - 100 42.2 - 100 
HIMS 42.2 45.8 12.0  0.0 0.0 100  0.0 0.0 100  - 100 11.5 - 100 
HPFS 23.9 42.8 33.3  12.5 37.5 50.0  0.0 6.0 94.0  4.3 8.6 7.7 8.6 11.2 
Janus part 1 1.2 5.0 93.7  20.7 69.2 10.1  27.0 56.2 16.9  - 100 - - 100 
Janus part 2 2.0 4.2 93.7  40.6 32.1 27.3  0.7 6.0 93.4  27.7 29.4 22.8 - 100 
JPHC 9.0 17.4 73.6  7.0 39.8 53.2  0.0 3.5 96.5  28.5 24.9 22.9 24.2 69.2 
MCCS 15.4 22.7 61.9  16.6 47.8 35.6  0.0 6.2 93.8  11.4 7.1 15.0 13.6 6.4 
MDCS 12.2 30.0 57.8  5.9 47.8 46.3  0.0 2.7 97.3  - 100 - - 100 
MEC 82.1 15.8 2.1  7.9 34.7 57.5  0.0 0.0 100  - 100 10.9 0.3 5.2 
PCPT 11.5 27.7 60.9  1.5 50.5 48.0  0.0 0.3 99.7  1.7 2.5 0.8 4.9 2.5 
PHS 7.6 17.0 75.5  11.8 50.7 37.5  25.6 59.9 14.6  13.7 3.8 24.6 10.1 3.6 
PLCO 56.4 39.1 4.6  7.5 52.2 40.3  0.0 0.0 100  18.6 0.0 7.6 10.7 0.3 
SELECT 39.9 58.3 1.8  10.4 56.3 33.3  0.0 0.0 100  1.0 1.4 1.2 7.0 13.6 
SU.VI.MAX 7.1 20.7 72.3  26.6 66.9 6.5  0.0 0.0 100  - 100 2.2 9.9 6.5 
a Percentages exclude cases with missing values. Percentages may not add up to 100 because of rounding. Stage and grade of disease are unavailable for some case patients; the percentages 
are shown in the “unknown stage” and “unknown grade” columns.  
b A tumour was categorised as advanced stage if it was tumor-node-metastasis (TNM) stage T3 or T4 and/or N1+ and/or M1, stage III–IV, or the equivalent. Aggressive disease was defined 
as tumours with TNM stage T4 and/or N1+ and/or M1 and/or stage IV disease and/or death from prostate cancer. High grade was defined as Gleason sum 8 or higher, or equivalent 
(undifferentiated).  
For expansion of study names see Table 1. Abbreviation: y, year.  
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Figure legends 
 
Figure 1. Odds ratios (95% confidence intervals) for prostate cancer associated with study-specific fifths of 
season-standardised 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentration in prospective studies.  
Estimates are from logistic regression conditioned on the matching variables and adjusted for exact age, marital status, 
education, smoking, height and body mass index. Ptrend was calculated by replacing the fifths of vitamin D with a 
continuous variable that was scored as 0, 0.25, 0.5, 0.75 and 1 in the conditional logistic regression model. Abbreviations: 
80%le= 80 percentile; CI = confidence interval; Ptr = Ptrend.  
 
Figure 2. Study-specific odds ratios (95% confidence intervals) for prostate cancer associated with an 80 
percentile increase in season-standardised 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentration. A) 
Blood season-standardised 25-hydroxyvitamin D concentration; B) Blood season-standardised 1,25-dihydroxyvitamin D 
concentration. 
Estimates are from logistic regression conditioned on the matching variables within each study and without mutual 
adjustment for the other analytes. Heterogeneity in linear trends between studies was tested by comparing the X2 values for 
models with and without a (studies) x (linear trend) interaction term. For expansion of study names see Table 1.  
              
Figure 3. Odds ratios (95% confidence intervals) for prostate cancer associated with a study-specific 80 
percentile increase in season-standardised 25-hydroxyvitamin D in prospective studies for selected subgroups.  
The odds ratios were conditioned on the matching variables and adjusted for exact age, marital status, education, smoking, 
height and body mass index. Tests for heterogeneity for the case-defined factors were obtained by fitting separate models for 
each subgroup and assuming independence of the ORs using a method analogous to a meta-analysis. Tests for heterogeneity 
for the other factors were assessed with a χ2-test of interaction between the subgroup and continuous trend test variable. Note 
that the number of cases for each tumour subtype may be fewer than shown in the baseline tables since here the analysis for 
each subgroup of a case-defined factor is restricted to complete matched sets for each category of the factor in turn; some 
matched sets contain a mixture of subtypes and while controls are allocated case-defined characteristics in equal proportion 
to the cases, 25(OH)D may be unknown for some participants, leading to incomplete matched sets.   
Stage (early, T1 and/or stage I; other localized, T2/N0/M0 and/or stage II, and advanced, T3-T4/N1/M1 and/or stage III-IV), 
grade (low-intermediate, Gleason sum was < 8 or equivalent; high, Gleason sum was ≥ 8 or equivalent, and aggressive 
(T4/N1/M1 and/or stage IV and/or prostate cancer death). White ethnicity (89.4% yes, 10.6% no). 
 
Figure 4. Odds ratios (95% confidence intervals) for prostate cancer associated with a study-specific 80 
percentile increase in 25-hydroxyvitamin D (A) and 1,25-dihydroxyvitamind D (B) concentration by season.  
The odds ratios were conditioned on the matching variables and adjusted for exact age, marital status, education, smoking, 
height and body mass index. Tests for heterogeneity were assessed with a χ2-test of interaction between the subgroup and 
continuous trend test variable. A) Blood 25-hydroxyvitamin D concentration; B) Blood 1,25-dihydroxyvitamin D 
concentration 
 
Figure 5. Geometric mean concentrations (95% confidence intervals) of season-standardised 25-
hydroxyvitamin D (nmol/L) for controls from all studies by various factors, adjusted for study and age at blood 
collection.  
Means are scaled to, and depicted as a proportion of, the overall geometric mean concentration (dotted line). P values are for 
tests of heterogeneity and, where applicable in parentheses, trend.   
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Supplementary methods 
Data collection 
The EHNBPCCG is described in detail elsewhere [1-7]. Published and unpublished studies were eligible 
for the current collaborative individual participant meta-analysis if they had data on pre-diagnostic circulating 
concentrations of 25(OH)D or 1,25(OH)2D and incident prostate cancers. Studies were identified through 
searches using the terms “vitamin D”, “25-hydroxyvitamin D”, “1,25 dihydroxyvitamin D”, and “prostate cancer” 
on computerized bibliographic systems, including PubMed, Web of Science, Cochrane Library, and CancerLit, 
through the reference lists of publications identified in this search, and through correspondence with study 
investigators. 
Individual participant data on circulating 25(OH)D for 13,462 men with prostate cancer and 20,261 
control participants were available from 19 prospective cohort studies by the date of dataset closure (May 2018): 
the Atherosclerosis Risk in Communities (ARIC) Study (unpublished, study described in [8], Alpha-Tocopherol, 
Beta-Carotene Cancer Prevention Study (ATBC) [9]; Campaign Against Cancer and Stroke (“Give Us a Clue to 
Cancer”) Study (CLUE) I [10]; Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und 
optimierten THerapie chronischer ERkrankungen in der älteren Bevölkerung (ESTHER) [11]; European 
Prospective Investigation into Cancer and Nutrition (EPIC) [12]; Finnish Mobile Clinic Health Examination 
Survey (FMC) (unpublished, study described in [13]); Health Professionals Follow-up Study (HPFS) [14-16]; 
Health In Men Study (HIMS) [17]; the Janus study that formed part of the of the Nordic Biological Specimen 
Biobank Working Group (Janus part 1) [18]; a second study using the Janus Serum Bank (Janus part 2) [19]; 
Japan Public Health Center–based Prospective (JPHC) Study [20]; Melbourne Collaborative Cohort Study 
(MCCS) (unpublished, study described in [21]); Malmö Diet and Cancer Study (MDCS) [22]; Multiethnic Cohort 
(MEC) [23]; Prostate Cancer Prevention Trial (PCPT) [24]; Physicians’ Health Study (PHS) [25-27]; Prostate, 
Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) [28]; Selenium and Vitamin E Cancer Prevention 
Trial (SELECT) [29]; and the SUpplémentation en VItamines et Minéraux AntioXydants (SU.VI.MAX) trial 
[30]. Data on 25(OH)D from seven relatively small studies (with a combined total of 1,047 cases) were not 
available for pooling: Helsinki Heart Study (HHS) [18, 31], Japan-Hawaii Cancer Study (JHCS) [32], Kaiser 
Permanente Medical Care Programme (KPMCP) [33, 34], The Osteoporotic Fractures in Men (MrOS) Study [35], 
Nutritional Prevention of Cancer (NPC) Trial [36], Northern Sweden Health and Disease Cohort (NSHDC) [18], 
and the Tromsø cohort study [37].  
 2 
Individual participant data on circulating 1,25(OH)2D for 1885 men with prostate cancer and 2114 control 
participants were available from three studies (CLUE I, HPFS and PHS) [10, 14, 25], but were not available for 
KPMCP [33, 34] or JHCS [32]. 
Individual participant data were requested on circulating 25(OH)D and 1,25(OH)2D, date, age and fasting 
status at sample collection, marital status, ethnicity, educational attainment, family history of prostate cancer, 
height, weight, waist and hip circumference, smoking status, alcohol intake, and vital status. Each study also 
provided data on prostate cancer stage and grade and death, if available, and the data were harmonized in a central 
database. 
Study designs and data processing 
Most of the studies were case-control studies nested within prospective cohort studies, with some 
variation between the studies in the case mix, related for example to the prevalence of Prostate Specific Antigen 
(PSA)-testing within that population during follow-up. Four studies (ARIC, ESTHER, HIMS, and MCCS) 
provided cohort data; therefore cases and controls were matched at the pooling center (University of Oxford) (for 
details about the matching criteria please see Supplementary Table 1). Two studies (PCPT and PLCO) were 
observational investigations based within randomized controlled trials that included organized screening for 
prostate cancer [24, 28]. For both these studies, men with a raised prostate specific antigen (PSA) or abnormal 
digital rectal examination at recruitment were excluded, and the majority of cases were detected either through 
subsequent PSA-screening (PLCO and PCPT) or by end-of-study biopsy (PCPT). Data on circulating 25(OH)D 
and 1,25(OH)2D for 1,424 prostate cancer cases and 1,440 control participants from a cross-sectional study within 
The Prostate Testing for Cancer and Treatment (ProtecT) trial were also available for analysis. In this study, all 
men with a PSA≥3 ng/mL at recruitment were offered diagnostic biopsy and those diagnosed at this time were 
included as cases for the observational study [38, 39]. Data on the control participants are included in cross-
sectional analyses of vitamin D concentrations in relation to participant characteristics, but because cases were 
diagnosed at the start of the study rather than during follow-up data, these data were not included in the main risk 
analyses.  
Details of the recruitment of participants, informed consent and ethics approvals are provided in the 
original publications [8-12, 14-20, 22-30, 38, 39]. 
Statistical analyses 
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The methods of analysis were similar to those described previously by this collaborative group [3, 5]. 
25(OH)D and 1,25(OH)2D concentrations were used as provided by the authors and were log-transformed to 
approximate a normal distribution for parametric analyses. To allow for the influence of month of blood draw on 
circulating concentrations, a regression model of log-transformed vitamin D concentration by month of blood 
collection (as a categorical variable) was fitted for each study; the “season-standardized” concentrations of 
25(OH)D and 1,25(OH)2D were then calculated by subtracting the residuals from each regression model from the 
study-specific mean log vitamin D concentration, and then exponentiating these values. Thus, the “season-
standardized” values represent vitamin D concentration ‘corrected’ for month of blood collection. All results are 
presented by season-standardized vitamin D, unless otherwise specified. 
The main method of analysis was logistic regression conditioned on the matching variables within each 
study. Men were categorized into fifths of the distribution of 25(OH)D and 1,25(OH)2D, with cut-points defined 
by the study-specific quintiles of the distribution within control participants, to allow for any systematic 
differences between the studies in assay methods and blood sample types [40]. In order to provide a summary 
measure of the OR, a linear trend was calculated by replacing the categorical variable representing the fifths of 
each analyte with a continuous variable that was scored as 0, 0.25, 0.5, 0.75, and 1; because the mid-points of the 
lowest and highest fifths are the 10th and 90th percentiles of the study-specific vitamin D concentration, a unit 
increase in this variable can be taken to represent an 80 percentile increase in the study-specific concentration of 
vitamin D. To assess the risk for prostate cancer risk in men with very low vitamin D concentrations, season-
standardized 25(OH)D was also categorized into study-specific tenths. 
To examine the effects of potential confounders (other than the matching criteria, which were taken into 
account in the study design and matched analyses), conditional logistic regression analyses were performed that 
included the following covariates: age at blood collection (continuous), body mass index (BMI, continuous), 
height (continuous), marital status  (married or cohabiting, not married or cohabiting, or not known), educational 
status (did not graduate from high school/secondary school/college, high school/secondary school/college 
graduates, university graduates, or not known) and cigarette smoking (never smoker, past smoker, current, or not 
known), all of which were associated with prostate cancer risk in these analyses. 
In a sensitivity analysis, conditional logistic regression models were also fitted using quintile cut-points 
defined by the overall distribution among the control participants in all studies combined; this approach 
maximizes the ability to examine associations across the full distribution of biomarker concentration across all 
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studies but assumes that the differences in absolute values between studies are due to true population differences, 
rather than due to assay differences between the studies. The analyses were also repeated using predefined 
categories for concentrations of 25(OH)D of <30, 30-<50, 50-<75 and ≥75 nmol/L, in order to investigate risks 
associated with very low (deficiency), low (insufficiency), moderate (sufficiency) and high circulating 
concentrations of vitamin D based on the Institute of Medicine (IoM) recommendations [41]. We also assessed 
whether circulating concentrations of vitamin D were related to death from prostate cancer. 
For each analyte, heterogeneity in linear trends between studies was assessed by comparing the χ2 values 
for models with and without a (study) x (linear trend) interaction term. To test whether the estimates for each 
analyte varied according to case characteristics, ORs were estimated within a series of subsets for the following 
characteristics: age at diagnosis, years from blood collection to diagnosis, year of diagnosis, stage of disease, 
aggressive disease, and grade of disease. Controls in each matched set were assigned the value of their matched 
case for the case-defined factors (e.g. age at diagnosis, years from blood collection to diagnosis). For the multi-
matched sets in PLCO in which the case characteristics varied (e.g. some low-intermediate grade, some high 
grade), controls were randomly allocated to cases in the same proportions. Tests for heterogeneity for the case-
defined factors (were obtained by fitting separate models for each subgroup and assuming independence of the 
ORs using a method analogous to a meta-analysis. Subgroup analyses were also conducted by age at blood draw, 
PSA at blood draw, university or higher education, BMI, cigarette smoking, alcohol consumption, season of 
blood draw, ethnicity and family history of prostate cancer. Tests for heterogeneity for these factors were assessed 
with a χ2-test of interaction between subgroup and the continuous trend test variable.  
In order to assess potential effect modification with different biomarkers, a χ2-test of interaction was used 
to determine whether risks by study-specific thirds of 25(OH)D varied according to study-specific thirds of 
1,25(OH)2D (and vice versa), and according to study-specific thirds of circulating concentrations of insulin-like 
growth factor-I (IGF)-I, IGF binding protein-3 (IGFBP3), testosterone, free testosterone, sex hormone-binding 
globulin (SHBG) and prostate-specific antigen (PSA), where these data were available. 
To explore the relationships between analytes, partial correlation coefficients between season-
standardized 25(OH)D and 1,25(OH)2D and other selected circulating biomarkers were calculated using 
standardized log-transformed concentrations among controls from each study, adjusting for age at blood 
collection and, in a second analysis, also for BMI. Standardization (by subtracting the mean log concentration and 
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dividing by the standard deviation of the log concentration) was performed to minimize for any systematic 
differences in the biomarker concentration between studies owing to differences in the assays.  
The cross-sectional associations of 25(OH)D and 1,25(OH)2D with participant characteristics (among the 
controls) were examined using analyses of variance to calculate geometric mean concentrations and 95% 
confidence intervals (CIs), adjusting for study and age at blood collection, as appropriate. F tests were used to test 
for heterogeneity in the geometric mean analyte concentrations between the categories, and where appropriate, to 
test for trends across the categories, with the ordered categories scored from 1 to the maximum number of 
categories.  
All tests of statistical significance were two-sided, and statistical significance was set at the 5% level. All 
statistical tests were carried out with Stata Statistical Software, Release 14 (StataCorp, LP, College Station, 
Texas). 
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Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010). MCCS: 
Cohort recruitment was funded by Cancer Council Victoria and VicHealth. The MCCS was further supported by 
Australian National Health and Medical Research Council (NHMRC) grants 209057 and 396414 and by 
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Supplementary tables and figures 
Supplementary Table 1. Study characteristics 
Study (First author, year) Sample population Location Recruitment 
period 
Prostate cancer 
ascertainment method 
Nested case-control study characteristics 
Ratio of case 
patients to 
control 
participants 
Matching criteria and comments 
ARIC (Unpublished)d Population-based cohort study USA 1987-1989 Cancer registry linkage 
supplemented with medical 
records; death certificates 
1:1-4 b Age at and date of blood collection (each ± 24 months), 
ethnicity, and requiring that controls had a vitamin D 
measurement if the matched case had one. 
ATBC (Albanes et al., 2011) Randomized trial of α-tocopherol 
and β-carotene among smokers 
Finland 1985-1988 Cancer registry linkage 1:1 Age at randomization (±1 year) and date of baseline 
blood collection (±30 days) 
CLUE 1 (Braun et al., 1995) Population-based cohort study USA 1974 Cancer registry linkage 1:2 Age (±1 year) 
EPIC (Travis et al., 2009) Population-based cohort study Europe 1991-2001 Cancer registry linkage; 
health insurance record 
linkage; Self-report with 
medical record review 
1:1 except for 
the Umeå 
center which 
was 1:2 
Study center, age enrolment (±6 months), time of blood 
draw (±1 hour), time between blood draw and last 
consumption of food/drink (<3 ,3-6, >6 hours; for Umeå 
<4, 4-8, >8 hours) 
ESTHER (Ordonez-Mena et al., 
2013) 
Population-based cohort study Germany 2000-2002 Active follow-up and record 
linkage with national and 
regional cancer registries 
1:4 b Age at blood collection (±12 months), month of the year 
(but not necessarily year) of blood collection (± 1 
month), fasting status, ethnicity, and family history of 
prostate cancer (where known for the case).  
FMC (unpublished)a  Population-based cohort study 
  
Finland 
  
1968-1972  Cancer registry linkage 1:2  Municipality (including time for blood collection), age 
(exact matching)    
HIMS (Wong et al., 2014)  Population-based cohort study 
 
Australia 1996-2004  Cancer registry linkage 1:4 b Age at blood collection (±12 months), date of blood 
collection (± 12 months), fasting status, and diabetes, and 
requiring that the controls in each matched set be 'alive 
and at risk' beyond the case's date of diagnosis 
HPFS (Platz  et al., 2004; 
Mikkah et al., 2007; Shui I et al., 
2012) 
Cohort study of male dentists, 
optometrists, osteopathic 
physicians, podiatrists, 
pharmacists, and veterinarians 
USA 1986 Self-report with medical 
record review; death 
certificates (for fatal) 
1:1 Year of birth (±1 year), date of recruitment (same year), 
time of blood collection (12 a.m.– 9 a.m., 9 a.m.–12 p.m., 
12 p.m.–4 p.m., 4 p.m.–12 a.m.), PSA test before blood 
draw (y/n), season of blood draw, control participants had 
≥1 screening PSA test after the date of blood draw     
Janus part 1 (Tuohimaa et al., 
2004) 
Population-based  cohort study of 
participants in county health 
examinations and blood donors 
Norway 1973-onward Cancer registry linkage 1:4 Age (±2 years), date (± 6 months) and season of blood 
draw and region 
Janus part 2 (Meyer et al., 2012) Participants in population-based 
health studies and had serum in the 
Janus Serum Bank  
Norway 1981-1991 Cancer registry linkage 1:1 Age at serum sampling (±6 months), date of serum 
sampling (±2 months) and county of residence (i.e. health 
examination)  
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JPHC (Sawada et al., 2017) Population-based cohort study Japan Cohort I – 
1990 
Cohort II - 
1993 
Hospital records and cancer 
registry linkage 
1:2 Age (±3 years), area (town or city, and village), public 
health center area, the date and time of day of blood 
collection (within 60 days and within 3 hours, 
respectively) and length of fasting time at blood sampling 
(within 3 hours). 
MCCS (unpublished)a Population-based cohort study Australia 1991-1994 Cancer registry linkage 1:1 or 1:2 b Age at blood collection (±24 months) and date of blood 
collection (±24 months), and requiring that the controls in 
each matched set be 'alive and at risk' beyond the case's 
date of diagnosis, and that controls had a vitamin D 
measurement if the matched case had one. Up to 2 
controls were matched with each case. 
MDCS (Brandstedt et al., 2012) Population-based cohort study Sweden 1991-1996 Cancer registry linkage 1:1 Calendar time at inclusion (±15 days), age at inclusion 
(±2 years) 
MEC (Park et al., 2010) Population-based cohort study USA 1993-1996 
(Blood 
collection 
2001-2006) 
Cancer registry linkage 1:2 Geographical location (California/Hawaii), ethnicity, 
birth year (±1 year), date blood draw (±6 months), time 
blood draw (±2 hours), fasting status (0<6, 6-<8, 8-<10, 
10+ hours) 
PCPT (Schenk et al., 2014) Randomized, placebo-controlled 
trial of finasteride and prostate 
cancer 
USA 1994-1997 Diagnosed as part of trial 
protocol. Annual digital rectal 
examinations and PSA 
measurements. Biopsy if 
abnormal DRE or  reported 
PSA level >4.0ng/ml. End-of-
study prostate biopsy 
1:1 Frequency matched: age (5-year age groups); PCPT 
treatment arm; positive family history for first-degree 
relative with prostate cancer. Controls required to have 
completed end of study biopsy procedure and had no 
evidence of prostate cancer.  
PHS (Gann et al., 1996; Ma et 
al., 1998; Li et al., 2007) 
Randomized trial of aspirin and β-
carotene among physicians 
USA 
  
1982-onward  Self-report with medical 
record review 
  
1:1-3 
  
Age (±1 year and ±5 years for older men), smoking status 
(never, former, current), length of follow-up. Participants 
included men from both placebo and treatment arms. 
Cases and controls were not matched by treatment arm 
but interaction analyses showed no modification of the 
vitamin D prostate cancer association by treatment arm.  
PLCO (Ahn  et al., 2008) Population-based randomized 
controlled multicenter trial of 
methods for early detection of 
cancer of the prostate, lung, 
colorectal and ovary. 
USA 1993-2001 Medical and pathology record 
review after screening and 
self-report with medical 
record review 
1:1 frequency 
matched 
Age at cohort entry (5-year intervals), time since initial 
screening (1-year time window), and calendar year of 
cohort entry. All study participants selected from trial 
screening arm, i.e. offered PSA at recruitment and 
annually for 5 years, plus DRE at recruitment and 
annually for three years. 
ProtecT (Gilbert  et al., 2011) Population-based PSA testing and 
randomized, controlled trial of 
treatments of localized prostate 
cancer 
United 
Kingdom 
2001-2009 
(Eligible for 
vitamin D 
study if 
recruited 
2003-2008) 
Diagnosed as part of trial 
protocol. PSA test at 
recruitment followed by 
diagnostic biopsy if PSA 
≥3ng/mL 
1:1 stratum 
matched 
5-year aged-band (age at PSA test) and GP/family 
practice, also by time and season of blood draw due to 
timing of recruitment clinic. (Vitamin D study nested 
within the prostate cancer detection phase of trial, 
controls with PSA <3.0ng/mL or raised PSA≥3.0 ng/mL 
combined with at least 1 negative biopsy) 
SELECT (Kristal et al., 2014) Randomized, placebo-controlled USA, July 2011- Most cases detected by PSA 1:3 for For each case men were selected for a subcohort at 
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trial of selenium and vitamin E in 
relation to prostate cancer risk 
Canada, 
Puerto 
Rico 
May 2004 and/or DRE screening, which 
was suggested annually but 
not required. Pathology 
reports and slides were 
obtained where possible.  
African 
American men 
1:1.15 for 
other men 
random from the same age/race group. 
Note that the SELECT intervention assignment was 
included as a covariate in the original multivariable 
regression models.  
SU.VI.MAX (Deschasaux et al., 
2016) 
Population-based, double-blind, 
placebo-controlled, randomized 
trial of supplementation with 
antioxidant vitamins and minerals 
(vitamin C, α-tocopherol, β-
carotene, selenium, and zinc)  
France 1994 Self-reported in a monthly 
questionnaire on health-
related events or detected 
through PSA screening of 
baseline bloods analyzed at 
the end of trial. PSA values 
PSA ≥ 4.0 μg/L were 
followed up. 
1:2 Men were matched on age at inclusion (<40/40–44/45–
49/50–54/55–65 years), intervention group of the initial 
SU.VI.MAX trial (placebo/antioxidants) and season of 
blood draw (a priori defined periods: June–
October/November–May) 
a Unpublished vitamin D and prostate cancer data, Study references: Joshu et al., 2018 for ARIC, Knekt et al., 2008 for FMC and Milne et al., 2017 for MCCS 
b Cases and controls were matched at the pooling center (University of Oxford) from the cohort study data provided. 
For expansion of study names see Table 1. 
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Supplementary Table 2. Assay details for 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D measurements 
Study (First author, 
year) 
Sample 25(OH)D assay  1,25(OH)2D assay Blinded Same batcha 
 Method (Manufacturer/ Laboratory) Intra-assay 
CV 
Inter-assay CV  Method (Manufacturer/ 
Laboratory) 
Intra-assay 
CV 
Inter-assay 
CV 
  
ARIC (Unpublished)d Serum Liquid chromatography-tandem high-
sensitivity mass spectrometry 
(University of Minnesota Molecular 
Epidemiology and Biomarker Research 
Laboratory, Minneapolis, MN, USA) 
- 20.8%  - - - Yes Not applicable 
– cohort 
ATBC (Albanes et al., 
2011) 
Serum DiaSorin Liaison platform Direct 
competitive chemiluminescence IA 
(Heartland Assays, Inc.) 
10.5% 12.3%  -  - - Yes Yes 
CLUE 1 (Braun et al., 
1995) 
Serum RIA (Hollis) 22.01% 11.1%  RRA (Hollis) 21.3% 14.3% Yes Yes 
EPIC (Travis et al., 2010) Serum EIA (Immunodiagnostic Systems, Ltd.) 3.9% - 14.8% 10.8% - 12.0%  -  - - Yes Yes 
ESTHER (Ordonez-Mena 
et al., 2013) 
 IDS-iSYS (Immunodiagnostic) <7.3% <8.9%. -  - - Yes Not applicable 
– cohort 
FMC (unpublished)b  Serum  EIA (Immuno Diagnostic Systems) - -  -  - - Yes NK 
HIMS (Wong et al., 2014) Plasma LIAISON 25 OH Vitamin D TOTAL 
chemiluminescence IA (DiaSorin Inc.) 
- 11.3 –  13.2%  - - - Not stated Not applicable 
– cohort 
HPFS (Platz et al., 2004; 
Mikkah et al., 2007; Shui 
et al., 2012) 
EDTA 
plasma 
RIA (Hollis) 5.4% - 14.8%  -  RIA (Hollis) 5.3% -7.3%  - Yes Yes 
Janus part 1 (Tuohimaa et 
al., 2004) 
Serum RIA (Incstar) 8.5% 16%  -  - - Yes Yes 
Janus part 2 (Meyer et al., 
2013) 
Serum HPLC atmospheric pressure chemical 
ionisation mass spectrometry (Vitas) 
 7.6% at 47.8 
nmol/L, 6.9% at 
83 nmol/L 
 - - - NK Yes 
JPHC (Sawada et al., 
2017) 
Plasma RIA (Mitsubishi Kagaku Bio-Clinical 
Laboratories Inc, Tokyo) 
8.9% -  - - - Yes Yes 
MCCS (unpublished)b  Dried 
blood 
spotsc 
LC-MS/MS (Queensland Brain 
Institute, University of Queensland) 
- 8.5%  - - - Yes Not applicable 
– cohort 
MDCS (Brandstedt et al., 
2012)  
Serum HPLC (Department of Clinical 
Chemistry, Skåne University Hospital) 
CVs were 8% 
at 65nmol/L, 
6.8% at 190 
nmol/L for 
25(OH)2D 
CVs were 8.5% 
at 70nmol/L, 
7.1% at 
210nmol/L for 
25(OH)3D 
 - - - NK Yes 
MEC (Park et al., 2010) Plasma IA (Immunodiagnostic Systems, Ltd.) 2% 3%  -  - - Not stated Yes 
 17 
PCPT (Schenk 2014) Serum LIAISON 25 OH Vitamin D TOTAL 
Assay (DiaSorin Inc.) 
CV 8.3%  - - - Yes ‘All batched 
balanced for 
cases and 
controls) 
PHS (Gann et al., 1996; 
Ma et al., 1998; Li et al., 
2007) 
Plasma RIA (Hollis) 7.9% -  RIA (Hollis) 8.1% - Yes Yes 
PLCO (Ahn et al., 2008) Serum RIA (Heartland Assays) Overall CV 5.9%  -  - - Yes Yes 
ProtecT (Gilbert et al., 
2011) 
Heparin 
plasma 
Tandem MS  - 4.2% - 5.7%  -  - - Not stated Not stated 
SELECT (Kristal et al., 
2014) 
Plasma LIAISON®25 OH Vitamin D TOTAL 
Assay (DIaSorin Inc., Stillwater) 
- 12.1% for the low 
QC and 6.9% for 
the high QC 
 - - - Yes Yes 
SU.VI.MAX (Deschasaux 
et al., 2016) 
Plasma Roche Cobas® 
electrochemiluminescence total 
25(OH)D assay (Roche Diagnostics) 
4.5% 6.6%  -  - - Yes NK 
a Cases and controls were assayed in the same batch.  
b Unpublished vitamin D and prostate cancer data, Study references: Joshu et al., 2018 for ARIC, Knekt et al., 2008 for FMC and Milne et al., 2017 for MCCS. 
c For MCCS, plasma concentrations were estimated from dried blood spots following the approach detailed in Heath AK et al., 2014. 
Abbreviations: CV, coefficient of variation; EDTA, Ethylenediaminetetraacetic acid; EIA, enzyme immunoassay; HPLC, high-performance liquid chromatography; IA, immunoassay, type unspecified; LC-MS/MS, liquid 
chromatography/tandem mass spectrometry; MS, mass spectrometry; NK, not known; RIA, radioimmunoassay; RRA, radioreceptor assay; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D. 
For expansion of study names see Table 1. 
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Supplementary Table 3. Odds ratios for prostate cancer by study-specific tenths of concentration of season-standardized 
25(OH)D among cases and their matched controls in prospective studies, conditioned on the matching variables and 
adjusted for exact age, marital status, education, smoking, height and body mass index. 
 25(OH)D 
Tenth OR (95% CI) 
1 1 (reference) 
2 1.12 (1.01-1.25) 
3 1.13 (1.01-1.25) 
4 1.14 (1.02-1.27) 
5 1.27 (1.14-1.42) 
6 1.16 (1.04-1.29) 
7 1.27 (1.14-1.41) 
8 1.28 (1.15-1.42) 
9 1.24 (1.12-1.39) 
10 1.34 (1.20-1.49) 
P for trend <0.001 
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Supplementary Table 4. Multivariable-adjusted odds ratios (95% confidence intervals) for prostate cancer in 
prospective studies by pre-specified categories of season-standardized 25-hydroxyvitamin D concentration 
Category 
(nmol/L) 
Cases/Controls 
Season-standardized 
25-hydroxyvitamin D 
 
 OR (95% CI) 
<30  919/1431 0.84 (0.76-0.93) 
30-49  3043/5163 0.89 (0.84-0.95) 
50-74 (reference) 5318/8018 1.00 (ref) 
≥ 75 4182/5649 1.07 (1.00-1.13) 
The odds ratios were conditioned on the matching variables and adjusted for exact age, marital status, education, smoking, height, 
and body mass index. Median concentrations of season-standardized 25(OH)D in each group were 23.8, 42.0, 61.5 and 89.7 
nmol/L, respectively. 
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Supplementary Table 5A. Multivariable-adjusted odds ratios for prostate cancer by study-specific thirds of 
concentration of season-standardized 25(OH)D and season-standardized 1,25(OH)2D, among cases and their matched 
controls in prospective studies. Data on both analytes were available for a total of 1885 cases and 2114 controls from 3 
studies (CLUE I, HPFS, PHS). 
  Odds ratio (95% confidence interval) 
  Third of 25(OH)D 
  1 2 3 
Third of 1,25(OH)2D 1 1 (reference) 0.96 (0.72-1.27) 1.00 (0.75-1.34) 
2 0.91 (0.69-1.20) 1.32 (1.01-1.73) 1.16 (0.87-1.54) 
 3 1.12 (0.83-1.52) 1.21 (0.91-1.59) 1.06 (0.81-1.39) 
P for interaction 0.23    
 
 
 
Supplementary Table 5B. Multivariable-adjusted odds ratios for prostate cancer by study-specific thirds of 
concentration of season-standardized 25(OH)D and IGF-I among cases and their matched controls in prospective studies. 
Data on both analytes were available for a total of 3050 cases and 4354 controls from 7 studies (EPIC phase 1, HIMS, 
HPFS, MEC, PCPT, PHS, SU.VI.MAX). 
  Odds ratio (95% confidence interval) 
  Third of 25(OH)D 
  1 2 3 
Third of IGF-I 1 1 (reference) 1.12 (0.91-1.39) 1.26 (1.02-1.56) 
2 1.07 (0.87-1.33) 1.19 (0.96-1.46) 1.22 (0.99-1.50) 
 3 1.10 (0.88-1.37) 1.27 (1.03-1.57) 1.31 (1.06-1.61) 
P for interaction 0.95    
 
 
 
Supplementary Table 5C. Multivariable-adjusted odds ratios for prostate cancer by study-specific thirds of 
concentration of season-standardized 25(OH)D and IGFBP-3 among cases and their matched controls in prospective 
studies. Data on both analytes were available for a total of 2971 cases and 4212 controls from 6 studies (EPIC phase 1, 
HIMS, HPFS, MEC, PCPT, PHS). 
  Odds ratio (95% confidence interval) 
  Third of 25(OH)D 
  1 2 3 
Third of IGFBP-3 1 1 (reference) 1.05 (0.84-1.30) 1.13 (0.91-1.42) 
2 1.09 (0.87-1.35) 1.32 (1.06-1.63) 1.38 (1.11-1.70) 
 3 1.18 (0.95-1.48) 1.31 (1.06-1.63) 1.38 (1.11-1.72) 
P for interaction 0.91    
 
 
 
Supplementary Table 5D. Multivariable-adjusted odds ratios for prostate cancer by study-specific thirds of 
concentration of season-standardized 25(OH)D and testosterone among cases and their matched controls in prospective 
studies. Data on both analytes were available for a total of 3003 cases and 6062 controls from 8 studies (EPIC phase 1, 
FMC, HIMS, JPHC, Janus part 1, MEC, PCPT, PHS). 
  Odds ratio (95% confidence interval) 
  Third of 25(OH)D 
  1 2 3 
Third of testosterone 1 1 (reference) 1.03 (0.85-1.24) 1.28 (1.05-1.55) 
2 0.98 (0.80-1.19) 1.05 (0.86-1.28) 1.27 (1.05-1.54) 
 3 0.98 (0.80-1.20) 1.06 (0.87-1.29) 1.08 (0.89-1.30) 
P for interaction 0.55    
 
  
 21 
Supplementary Table 5E. Multivariable-adjusted odds ratios for prostate cancer by study-specific thirds of 
concentration of season-standardized 25(OH)D and free testosterone among cases and their matched controls in 
prospective studies. Data on both analytes were available for a total of 2969 cases and 6062 controls from 8 studies 
(EPIC phase 1, FMC, HIMS, JPHC, Janus part 1, MEC, PCPT, PHS). 
  Odds ratio (95% confidence interval) 
  Third of 25(OH)D 
  1 2 3 
Third of free 
testosterone 
1 1 (reference) 1.07 (0.88-1.30) 1.29 (1.06-1.57) 
2 1.08 (0.88-1.31) 1.10 (0.91-1.34) 1.27 (1.05-1.55) 
 3 0.98 (0.80-1.21) 1.07 (0.87-1.31) 1.18 (0.97-1.43) 
P for interaction 0.95    
 
 
 
Supplementary Table 5F. Multivariable-adjusted odds ratios for prostate cancer by study-specific thirds of 
concentration of season-standardized 25(OH)D and SHBG among cases and their matched controls in prospective studies. 
Data on both analytes were available for a total of 3088 cases and 6254 controls from 8 studies (EPIC phase 1, FMC, 
HIMS, JPHC, Janus part 1, MEC, PCPT, PHS). 
  Odds ratio (95% confidence interval) 
  Third of 25(OH)D 
  1 2 3 
Third of SHBG 1 1 (reference) 0.97 (0.80-1.17) 1.14 (0.94-1.38) 
2 0.91 (0.75-1.10) 0.96 (0.80-1.16) 1.15 (0.95-1.38) 
 3 0.81 (0.66-0.99) 0.93 (0.76-1.13) 1.03 (0.85-1.25) 
P for interaction 0.78    
 
 
 
Supplementary Table 5G. Multivariable-adjusted odds ratios for prostate cancer by study-specific thirds of 
concentration of season-standardized 25(OH)D and PSA among cases and their matched controls in prospective studies. 
Data on both analytes were available for a total of 4470 cases and 5111 controls from 8 studies (EPIC phase 1, Janus part 
1, MEC, PCPT, PHS, PLCO, SELECT, SU.VI.MAX) 
  Odds ratio (95% confidence interval) 
  Third of 25(OH)D  
  1 2 3 
Third of PSA 1 1 (reference) 1.38 (1.00-1.88) 1.09 (0.78-1.52) 
2 3.01 (2.26-4.01) 3.13 (2.36-4.16) 3.33 (2.51-4.43) 
 3 14.1 (10.8-18.4) 16.0 (12.2-20.9) 17.6 (13.5-23.1) 
P for interaction 0.36    
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Supplementary Table 6. Partial correlations among controls in all studies between log-transformed concentrations of 
circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and other analytes, standardized within each study and 
adjusted for age at blood collection (5 age-groups). 
 
Observed 
25(OH)D c 
Season-
standardized 
25(OH)D 
1,25(OH)2D 
Season-
standardized 
1,25(OH)2D 
Season-standardized 25(OH)D 0.95b - - - 
 (21,701)    
1,25(OH)2D 0.14b 0.13b - - 
 (3398)    
Season-standardized 1,25(OH)2D 0.12b 0.13b 0.99b - 
 (3398)  (3384)  
IGF-I 0.05b 0.06b 0.03 0.04 
 (5660)  (1893)  
IGF-II 0.06a 0.07b 0.03 0.03 
 (3061)  (1101)  
IGFBP-1 0.11b 0.12b 0.10a 0.11a 
 (2761)  (834)  
IGFBP-2 0.10b 0.10b -0.04 -0.04 
 (1996)  (1019)  
IGFBP-3 0.05b 0.06b 0.06a 0.07a 
 (5326)  (1882)  
SHBG 0.08b 0.08b 0.04 0.04 
 (6307)  (219)  
Testosterone 0.09b 0.10b -0.01 -0.01 
 (6256)  (219)  
Free testosterone 0.05b 0.06b -0.02 -0.01 
 (6235)  (219)  
Estradiol -0.01 -0.01 (<10 obs) (<10 obs) 
 (2224)    
Free Estradiol -0.04a -0.04a (<10 obs) (<10 obs) 
 (2220)    
Insulin -0.08b -0.08b -0.09 -0.11 
 (3441)  (33)  
C-peptide -0.11b -0.12b -0.13b -0.13b 
 (2166)  (849)  
Lycopene 0.07b 0.05a -0.00 0.00 
 (3483)  (1192)  
Prostate-specific antigen 0.01 0.01 0.01 0.01 
 (6768)  (1816)  
a Two -sided significance level P <0.05 
b Two-sided significance level P <0.001 
c Numbers in parentheses are numbers of controls with data on both analytes 
Abbreviations: IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; SHBG, sex hormone binding 
globulin;  
25(OH)D,25-hydroxyvitamin D ; 1,25(OH)2D, 1,25-dihydroxyvitamin D. 
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A. 25-hydroxyvitamin D (nmol/L) 
 
 
 
B. 1,25 dihydroxyvitamin D (pmol/L) 
 
 
Supplementary Figure 1. Geometric mean concentrations (95% confidence intervals) of 25-hydroxyvitamin D (nmol/L) and 1,25 
dihydroxyvitamin D (pmol/L) for all prospective studies by month of blood collection (corrected for hemisphere so that January is treated 
as July, February as August, and so on for the HIMS and MCCS studies) and case-control status, adjusted for study and age at blood 
collection. The geometric means among case patients are depicted by solid circles and among control participants by open circles. 
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A. Study-specific cut-points    
 
 
 
 
B. Overall cut-points (across all prospective studies combined) 
 
 
 
Supplementary Figure 2. Odds ratios (95% confidence intervals) for prostate cancer associated with study-specific and overall 
fifths of concentrations of season-standardised 25-hydroxyvitamin D and 1,25-dihydroxyvitamind D concentration in prospective 
studies.  
Estimates are from logistic regression conditioned on the matching variables within each study, and without mutual adjustment for the other 
analyte. Ptrend was calcuated by replacing the fifths of concentration with a continuous variable that was scored 0, 0.25, 0.5, 0.75 and 1 in the 
conditional logistic regression model. Median concentrations in each fifth (using overall cut-points) are: 33.6, 48.6, 60.1, 73.3 and 96.1 nmol/L, 
respectively, for season-standardized 25-hydroxyvitamin D and 57.2, 72.8, 84.7, 97.7 and 122.2 pmol/L, respectively, for season-standardized 
1,25-dihydroxyvitamind D. Abbreviations: 80%le = 80 percentile; CI = confidence interval; Ptr = Ptrend.  
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Supplementary Figure 3. Odds ratios (95% confidence intervals) for prostate cancer associated with overall (across all 
prospective studies combined) fifths of season-standardized 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentration in 
prospective studies.  
Estimates are from logistic regression conditioned on the matching variables and adjusted for exact age, marital status, education, smoking, 
height and body mass index. Ptrend was calculated by replacing the fifths of vitamin D with a continuous variable that was scored as 0, 0.25, 
0.5, 0.75 and 1 in the conditional logistic regression model. Median concentrations in each fifth are: 33.2, 48.6, 60.3, 74.0 and 97.8 nmol/L, 
respectively, for season-standardized 25-hydroxyvitamin D and 57.2, 72.8, 84.7, 97.7 and 122.2 pmol/L, respectively, for season-standardized 
1,25-dihydroxyvitamind D. Abbreviations: 80%le= 80 percentile; CI = confidence interval; Ptr = Ptrend.  
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A. Advanced stage prostate cancer a   
 
B. Aggressive prostate cancer b    
 
 
C. High grade prostate cancer c 
 
 
Supplementary Figure 4. Odds ratios (95% confidence intervals) for advanced stage, aggressive and high grade prostate cancer 
associated with study-specific fifths of season-standardized 25-hydroxyvitamin in prospective studies.  
Estimates are from logistic regression conditioned on the matching variables and adjusted for exact age, marital status, education, smoking, 
height and body mass indexa. Abbreviations: 80%le= 80 percentile; CI = confidence interval; Ptr = Ptrend. 
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Ptrend (Ptr) was calculated by replacing the fifths of vitamin D with a continuous variable that was scored as 0, 0.25, 0.5, 0.75 and 1 in the 
conditional logistic regression model. 
a Prostate cancer was defined as being “advanced” stage if it was tumor-node-metastasis (TNM) stage T3 or T4 and/or N1+ and/or M1, stage III–
IV, or the equivalent (that is, a tumor extending beyond the prostate capsule and/or lymph node involvement and/or distant metastases).  
b Prostate cancer was defined as being aggressive disease if it was TNM stage T4 and/or N1+ and/or M1 and/or stage IV disease and/or death 
from prostate cancer. 
c Prostate cancer was defined as high-grade if the Gleason sum was at least 8 or equivalent (i.e. undifferentiated).  
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Supplementary Figure 5. Odds ratios (95% confidence intervals) for prostate cancer associated with an 80 percentile increase in 
season-standardized 1,25 dihydroxyvitamin D in prospective studies for selected subgroups. 
The odds ratios were conditioned on the matching variables and adjusted for exact age, marital status, education, smoking, height and body mass 
index. Tests for heterogeneity for the case-defined factors were obtained by fitting separate models for each subgroup and assuming 
independence of the ORs using a method analogous to a meta-analysis. Tests for heterogeneity for the other factors were assessed with a χ2-test 
of interaction between the subgroup and continuous trend test variable. Note that the number of cases for each tumor subtype may be fewer than 
shown in the baseline tables since here the analysis for each subgroup of a case-defined factor is restricted to complete matched sets for each 
category of the factor in turn; some matched sets contain a mixture of subtypes and while controls are allocated case-defined characteristics in 
equal proportion to the cases, 1,25(OH)2D may be unknown for some participants, leading to incomplete matched sets.   
Stage (early, T1 and/or stage I; other localized, T2/N0/M0 and/or stage II, and advanced, T3-T4/N1/M1 and/or stage III-IV), grade (low-
intermediate, Gleason sum was < 8 or equivalent; high, Gleason sum was ≥ 8 or equivalent, and aggressive (T4/N1/M1 and/or stage IV and/or 
prostate cancer death).           
 29 
 
 
Supplementary Figure 6. Geometric mean concentrations (95% confidence intervals) of season-standardized 1,25 
dihydroxyvitamin D (pmol/L) for controls from all studies by various factors, adjusted for study and age at blood collection.  
Means are scaled to, and depicted as a proportion of, the overall geometric mean concentration (dotted line). P values are for tests of 
heterogeneity and, where applicable in parentheses, trend.   
 
 
